WCM Investment Management LLC Reduces Position in STERIS plc (NYSE:STE)

WCM Investment Management LLC decreased its stake in shares of STERIS plc (NYSE:STEFree Report) by 3.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,497,191 shares of the medical equipment provider’s stock after selling 183,346 shares during the period. STERIS accounts for 2.2% of WCM Investment Management LLC’s investment portfolio, making the stock its 16th biggest position. WCM Investment Management LLC owned approximately 4.56% of STERIS worth $922,284,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Ashton Thomas Securities LLC purchased a new position in STERIS during the third quarter worth $25,000. Central Pacific Bank Trust Division increased its position in STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 76 shares in the last quarter. Quarry LP purchased a new position in STERIS during the third quarter worth $67,000. Asset Dedication LLC increased its position in STERIS by 54.8% during the third quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock worth $71,000 after buying an additional 103 shares in the last quarter. Finally, R Squared Ltd purchased a new position in STERIS during the fourth quarter worth $78,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Activity

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,471,363.04. The trade was a 12.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.14% of the company’s stock.

STERIS Stock Down 1.0 %

NYSE:STE opened at $223.13 on Friday. The firm has a market capitalization of $22.03 billion, a PE ratio of 47.37 and a beta of 0.84. The stock has a 50 day moving average of $212.57 and a 200-day moving average of $224.56. STERIS plc has a 52 week low of $197.82 and a 52 week high of $248.24. The company has a current ratio of 2.13, a quick ratio of 1.55 and a debt-to-equity ratio of 0.32.

STERIS (NYSE:STEGet Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Analysts predict that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.02%. STERIS’s dividend payout ratio (DPR) is presently 48.41%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Thursday. Stephens reaffirmed an “overweight” rating and issued a $240.00 price objective on shares of STERIS in a research report on Thursday. Piper Sandler lifted their price objective on STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and an average target price of $258.75.

Check Out Our Latest Stock Report on STE

STERIS Company Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Read More

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.